10% Owner RA Capital Sells $173K in Werewolf Therapeutics Shares Amidst Distress
HOWL is trading near its 52-week low of $0.355 (3.4% above the low).
Summary
A major institutional investor, RA Capital, sold a significant block of Werewolf Therapeutics shares, signaling reduced confidence as the company faces going concern issues and explores strategic options.
Key Events · Ownership and Investor Activity · HOWL
-
Institutional Investor Sells Shares
RA Capital Healthcare Fund LP, a 10% owner, sold 448,836 shares of Werewolf Therapeutics common stock for a total value of $173,758 between June 12-16, 2026.
-
Significant Stake Reduction
The sale represents approximately 0.99% of the company's market capitalization, indicating a notable reduction in exposure by a major institutional holder.
-
Amidst Company Distress
This transaction occurs as Werewolf Therapeutics faces substantial doubt about its ability to continue as a going concern and is actively exploring strategic alternatives, including a potential sale.
-
Reinforces Distribution Trend
This sale by RA Capital follows a broader pattern of institutional distribution observed in recent filings from other major investors like MPM Asset Management.
Analysis · HOWL · Life Sciences
RA Capital, a 10% owner, sold nearly $174,000 worth of Werewolf Therapeutics stock. This sale, representing almost 1% of the company's market cap, adds to a pattern of institutional distribution. It occurs while the company is exploring strategic alternatives, has expressed substantial doubt about its ability to continue as a going concern, and its stock is trading near 52-week lows. This indicates a lack of confidence from a major institutional investor during a critical period for the company.
At the time of this filing, HOWL was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.5M. The 52-week trading range was $0.36 to $2.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.